- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide, sitagliptin, placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK2330672, Placebo, Sitagliptin, Metformin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years to 64 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Bexagliflozin, Sitagliptin, Placebo for sitagliptin, Placebo for bexagliflozin
- Drug
- Lead sponsor
- Theracos
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Lincoln, California • Long Beach, California • San Dimas, California + 7 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 45
- States / cities
- Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
- Conditions
- Type 2 Diabetes
- Interventions
- SK-0403, Placebo, Sitagliptin
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 37 more
- Conditions
- Type 2 Diabetes
- Interventions
- Sitagliptin, Placebo
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- South Burlington, Vermont
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- sitagliptin, Placebo
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Dyslipidaemias
- Interventions
- an undetermined dose of GSK1292263, ascending dose of GSK1292263
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Placebo, PF-04937319 - 3mg, PF-04937319 - 20mg, PF-04937319 - 50mg, PF-04937319 - 100mg, Sitagliptin - 100mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 24
- States / cities
- Anaheim, California • Los Angeles, California • Spring Valley, California + 18 more
- Conditions
- HIV-1 Infection
- Interventions
- Sitagliptin, Placebo for sitagliptin
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Torrance, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Sitagliptin, Placebo Oral Tablet
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 13 Years to 30 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Obesity
- Interventions
- Exendin 9-39 and Sitagliptin, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- DA-1241, Placebo, Sitagliptin
- Drug
- Lead sponsor
- Dong-A ST Co., Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Miami, Florida • High Point, North Carolina + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- Placebo, Roflumilast/Sitagliptin, Sitagliptin, Roflumilast
- Other
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sitagliptin, Placebo, Neuropeptide Y, Enalaprilat, Valsartan 160mg
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sitagliptin phosphate, Placebo
- Drug · Other
- Lead sponsor
- Blandine Laferrere
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type II Diabetes
- Interventions
- Sitagliptin, Placebo
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Diabetes Type I
- Interventions
- sitagliptin, Placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK1292263, GSK1292263 matching placebo, Sitagliptin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
- Conditions
- Type 1 Diabetes
- Interventions
- Sitagliptin and Lansoprazole, Placebo
- Drug
- Lead sponsor
- Sanford Health
- Other
- Eligibility
- 11 Years to 45 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK256073 1mg, GSK256073 5mg, GSK256073 10mg, GSK256073 25mg, Placebo, Sitagliptin 100mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Anniston, Alabama • Miami, Florida • Miramar, Florida
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Fasiglifam (TAK-875), Fasiglifam (TAK-875) Placebo, Sitagliptin, Sitagliptin Placebo, Metformin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 44
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 41 more